Asensus Surgical (ASXC) Stock Price, News & Analysis

Company Overview

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $0.35 to $0.35
• 50-Day Range: N/A
• 52-Week Range: $0.17 to $0.40
• Volume: N/A
• Average Volume: 2.03 million shs
• Market Capitalization: $94.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.35
• Consensus Rating: Hold

Asensus Surgical Stock Analysis - MarketRank™

Asensus Surgical scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Asensus Surgical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Asensus Surgical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Asensus Surgical are expected to grow in the coming year, from ($0.24) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Asensus Surgical is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Asensus Surgical is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Asensus Surgical has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ASXC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Asensus Surgical does not currently pay a dividend.

Dividend Growth

Asensus Surgical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ASXC.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for ASXC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Asensus Surgical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.87% of the stock of Asensus Surgical is held by insiders.

Percentage Held by Institutions

Only 9.35% of the stock of Asensus Surgical is held by institutions.

ASXC Stock Analysis - Frequently Asked Questions

How have ASXC shares performed this year?

Asensus Surgical's stock was trading at $0.3479 on January 1st, 2025. Since then, ASXC shares have increased by 0.0% and is now trading at $0.3479.
View the best growth stocks for 2025 here.

How were Asensus Surgical's earnings last quarter?

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) posted its earnings results on Wednesday, November, 3rd. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The company had revenue of $2.57 million for the quarter, compared to analyst estimates of $1.02 million. Asensus Surgical had a negative net margin of 902.25% and a negative trailing twelve-month return on equity of 184.10%.

How do I buy shares of Asensus Surgical?

Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Asensus Surgical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Asensus Surgical investors own include Digital Turbine (APPS), CrowdStrike (CRWD), ChargePoint (CHPT), SoFi Technologies (SOFI) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/03/2021
• Today: 4/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:ASXC
• CIK: N/A
• Web: www.asensus.com
• Phone: (919) 765-8400
• Fax: 919-765-8459
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $0.35
• High Stock Price Target: $0.35
• Low Stock Price Target: $0.35
• Potential Upside/Downside: +0.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-78,430,000.00
• Net Margins: -902.25%
• Pretax Margin: -899.16%
• Return on Equity: -184.10%
• Return on Assets: -114.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.00
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $8.58 million
• Price / Sales: 11.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 272,330,000
• Free Float: 264,516,000
• Market Cap: $94.74 million
• Optionable: Not Optionable
• Beta: 1.37